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Background: MicroRNAs (miRNAs) have been documented as playing important roles in cancer development. In
this study, we investigated the role of miR-124 in breast cancer and clarified the regulation of flotillin-1 (FLOT1) by
miR-124.
Methods: The expression levels of miR-124 were examined in breast cancer cell lines and patient specimens using
quantitative reverse transcription-PCR. The clinicopathological significance of the resultant data was later analyzed.
Next, we explored the function of miR-124 to determine its potential roles on cancer cell growth and migration
in vitro. A luciferase reporter assay was conducted to confirm the target gene of miR-124, and the results were
validated in cell lines and patient specimens.
Results: We found that miR-124 expression was significantly downregulated in breast cancer cell lines and patient
specimen compared with normal cell lines and paired adjacent normal tissues (P < 0.0001), respectively. MiR-124
was also associated with tumor node metastasis (TNM) stage (P = 0.0007) and lymph node metastasis (P = 0.0004). In
breast cancer cell lines, the ectopic expression of miR-124 inhibited cell growth and migration in vitro. Moreover, we
identified the FLOT1 gene as a novel direct target of miR-124, and miR-124 ectopic expression significantly inhibited
FLOT1. Luciferase assays confirmed that miR-124 could directly bind to the 3′ untranslated region of FLOT1 and
suppress translation. Moreover, FLOT1 was widely upregulated, and inversely correlated with miR-124 in breast
cancer tissues. Consistent with the effect of miR-124, the knockdown of FLOT1 significantly inhibited breast cancer
cell growth and migration. We also observed that the rescue expression of FLOT1 partially restored the effects of
miR-124.
Conclusions: Our study demonstrated that miR-124 might be a tumor suppressor in breast cancer via the
regulation of FLOT1. This microRNA could serve as a potential diagnostic marker and therapeutic target for breast
cancer.
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Breast cancer is the leading cause of cancer death in fe-
males worldwide. Due to the advances in diagnosis and
appropriately systemic therapy, including surgery, radi-
ation and chemotherapy, the prognosis of breast cancer
is encouraging. However, similar to many other solid tu-
mors, distant metastases account for more than 90% of
breast cancer-related death [1]. Because the underlying* Correspondence: 13711694565@163.com
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reproduction in any medium, provided the ormechanisms of breast cancer metastasis consist of mul-
tiple sequential steps that are not completely understood
to date, further investigation of this mechanism is ur-
gently needed.
MicroRNAs (miRNAs) are endogenous noncoding small
RNAs that contribute to the regulation of their cognate
target genes by usually imperfect base-pairing to the 3′ un-
translated region (UTR) of a target mRNA, which results
in either mRNA degradation or translation inhibition [2].
In fact, miRNAs are implicated in the regulation of various
cellular processes, including proliferation, differentiation,
cell death and cell mobility [3]. Furthermore, miRNAhis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Li et al. Molecular Cancer 2013, 12:163 Page 2 of 13
http://www.molecular-cancer.com/content/12/1/163profiles also indicate that miRNAs can function either as
oncogenes or tumor suppressors in tumor progression
[4,5]. Therefore, miRNA expression profiles constitute
progress in cancer diagnosis, classification, clinical prog-
nostic information and therapy [6-10].
Previous studies of miRNA profiles demonstrated sev-
eral deregulated miRNAs in breast cancer, including miR-
124 [11-13]. MiR-124, a brain-enriched miRNA, was first
found to be involved in stem cell regulation and neurode-
velopment [14,15]. Previous research confirmed that miR-
124 is epigenetically silenced in various types of cancer
and regulated cancer cell biological behaviors by targeting
several important genes, such as sphingosine kinase 1
(SPHK1), rho-kinase2 (ROCK2), enhancer of zeste ho-
mologue 2 (EZH2), RAC1, the androgen receptor and
CD151 [16-20]. Recent studies further revealed that miR-
124 plays important roles in the regulation of growth, me-
tastasis and epithelial-mesenchymal transition (EMT) in
breast cancer [16,21,22]. These studies suggested that
miR-124 can serve as a potential tumor suppressor. Our
study showed that miR-124 was downregulated in breast
cancer, and a bioinformatic analysis predicted flotillin-1
(FLOT1) to be a potential target of miR-124.
FLOT1 is overexpressed in several types of cancer, in-
cluding breast cancer [23-26]. FLOT1 was originally
identified as a marker of lipids, which is important for
non-caveolar raft formation and associated with the de-
velopment and progression of cancer. In breast cancer,
the FLOT1 expression level correlated with clinical sta-
ging and prognosis, and its silencing inhibited the prolif-
eration and tumorigenicity of breast cancer cells in vitro
and vivo [26]. MicroRNAs can regulate the expression
levels of FLOT1 [27], a process that was intensively
studied by our group. Our findings, consistent with
other groups, indicated that the role of miR-124 in the
growth and metastasis inhibition was accomplished by
the regulation of FLOT1 in breast cancer.
In this study, we aimed to investigate the role of miR-
124 in breast cancer. We found that downregulation of
miR-124 in breast cancer tissues compared with the cor-
responding normal tissues, and inversely associated with
TNM stage and lymph node metastasis in breast cancer.
In addition, synthetic miR-124 mimics inhibited the
growth and migration of breast cancer cells in vitro. Fur-
thermore, we validated FLOT1, which was overexpressed
in breast cancer and predicted as the target of miR-124,
by 3′-UTR luciferase assays and western blot analysis.
Finally, knockdown of FLOT1 consistent with the effects
of miR-124 in breast cancer, and rescue expression of
FLOT1 could partially restore these miR-124 effects.
Our study demonstrated that miR-124 acts as a tumor
suppressor by directly targeting FLOT1 in breast cancer,
which suggested that miR-124 has potential diagnostic
and therapeutic value for breast cancer treatment.Results
MiR-124 was downregulated in breast cancer cell lines
and clinical specimens and inversely associated with
advanced clinical stage and lymph node metastasis
To study the expression level of miR-124 in breast cancer,
a panel of breast cancer cell lines was first analyzed by
stem-loop RT-PCR. Compared with the two immortalized
normal mammary epithelial cell lines (184A1, MCF-10A),
miR-124 expression level was downregulated in all 7
breast cancer cell lines (MDA-MB-231, MDA-MB-361,
MDA-MB-435, MDA-MB-468, MCF-7, HBL100, T47D,
4 T1) (Figure 1A).
We further assessed the expression levels of miR-124
in 78 clinical human primary breast cancer tissues and
40 paired normal adjacent tissues (NATs) to analyze the
clinicopathologic significance of the miR-124. The rela-
tionship between the miR-124 expression levels and clin-
icopathologic characteristics in breast cancer patients
are summarized in Table 1. Consistent with the result
obtained from breast cancer cell lines, the average ex-
pression level of miR-124 was downregulated in breast
cancer tissues compared with paired normal adjacent tis-
sues (Figure 1B; P < 0.0001). We divided 78 breast cancer
cases into two groups according to the status of lymph
node metastasis: lymphatic node metastasis positive or
negative. Interestingly, the breast cancer lymphatic node
metastasis positive group (n = 37) showed an even lower
miR-124 expression level than the lymphatic node me-
tastasis negative group (n = 41; Figure 1C; P = 0.0004). In
addition, we also found that the expression of miR-124
was lower in advanced TNM stage breast cancer patients
(stage III and IV) than early stage patients (stage I and
II; Figure 1D and Table 1). Taken together, these results
indicated that miR-124 is downregulated in breast can-
cer, and a reduced expression of miR-124 may play an
important role in the progression and metastasis of
breast cancer.
Ectopic expression of miR-124 inhibited the proliferation,
migration and invasion of breast cancer cells
To investigate the effect of miR-124 on cell proliferation,
we transfected the breast cancer cell lines MDA-MB-231
and T47D with miR-124 mimics. The successful overex-
pression of miR-124 in the cells was confirmed by quan-
titative real-time PCR (Figure 2A). MTT and colony
formation assays showed that ectopic expression of miR-
124 could markedly inhibit the proliferation and growth
of MDA-MB-231 and T47D cells compared with the
mimic control (Figure 2B and D; P < 0.05). This anti-
proliferation effect could be partially due to the disrup-
tion of cell growth regulation, such as cell cycle arrest.
Thus, we next explored the effect of miR-124 on cell
cycle regulation. Flow cytometric cell cycle analysis
showed that miR-124 increased the number of cells in
Figure 1 miR-124 is downregulated in breast cancer cell lines and human breast cancer specimens, and the reduced expression is
associated with advanced clinical stage and positive lymph node metastasis in breast cancer patients. A, Expression of miR-124 in 7
breast cancer cell lines and 2 normal breast epithelial cell lines; miR-124 expression was determined by qRT-PCR and normalized to 5S rRNA.
B, Expression of miR-124 in 78 cases of human breast cancer and 40 corresponding normal adjacent tissues. C, Expression levels of miR-124 are
associated with lymph node metastasis of breast cancer (P = 0.0004). D, Expression levels of miR-124 in different clinical stages of breast cancer patients
(P = 0.0004). Statistical analysis is performed using the paired t-test (B) and the Student t-test (C and D). Data are shown as the mean ± SEM.
NATs: normal adjacent tissues.
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in the S and G2 +M phase in the MDA-MB-231 and
T47D breast cancer cell lines compared with miR-Ctrl
(Figure 2C).
After confirming the cell proliferation and growth in-
hibition ability of miR-124, we investigated the role of
miR-124 in cell migration and invasion. Wound healing
and Matrigel invasion assays demonstrated that the ec-
topic expression of miR-124 inhibited the cell migration
and invasion of MDA-MB-231 and T47D cells compared
with the mimic control (Figure 2E and F). The above re-
sults support the role of miR-124 in the inhibition of
breast cancer proliferation, migration and invasion and
suggest that miR-124 has a tumor suppressor function.
MiR-124 downregulated FLOT1 expression by directly
targeting its 3′-UTR
To elucidate the molecular mechanism responsible for
the proliferation and migration inhibition induced by
miR-124 in breast cancer cells, we used a bioinformatic
analysis to search for putative protein-coding gene tar-
gets of miR-124, especially for those that can promote
cancer cell growth and metastasis. According to this ra-
tionale, FLOT1 was selected as one of the candidatetargets of miR-124, which was highly conserved among
different species and whose 3′-UTR of mRNA contained
a complementary site for the seed region of miR-124
(Figure 3A).
We performed a luciferase reporter assay to determine
whether FLOT1 is a direct target of miR-124 in breast
cancer cells. The target region sequence of FLOT1 3′-
UTR (wt 3′-UTR) or the mutant sequence (mut 3′-UTR)
was cloned into a luciferase reporter vector (Figure 3B).
These constructed reporter vectors were co-transfected
with miR-124 mimics or miR-Ctrl into the MDA-MB-231
cell line. The data in Figure 3C show that miR-124 could
downregulate the luciferase activity of the FLOT1 wt 3′-
UTR construct (Figure 3C, lanes 3; P < 0.05), whereas the
luciferase activity was not significantly attenuated in the
target region of the mutated mut 3′-UTR construct
(Figure 3C, lanes 4, 5 and 6). These data suggest that the
regulation of miR-124 on FLOT1 depended on the specific
seed region sequence. Moreover, miR-Ctrl did not signifi-
cantly affect the luciferase activity of either the wt or mut
3′-UTR construct (Figure 3C, lanes 2 and 5).
We further analyzed the FLOT1 protein expression by
using western blotting after transfecting MDA-MB-231
and T47D cells with miR-124 mimics. As shown in
Table 1 The relationship between miR-124 expression









≤45 38 0.4252 ± 0.0403 0.0372
>45 40 0.3140 ± 0.0338
Tumor size (cm)
≤2 25 0.4107 ± 0.0573 0.2781
>2 53 0.3481 ± 0.0287
TNM stage
I + II 62 0.4128 ± 0.0307 0.0007
III + IV 16 0.1951 ± 0.0231
Lymph node metastasis
No 41 0.4550 ± 0.0407 0.0004
Yes 37 0.2720 ± 0.0265
ER status
Negative 25 0.3575 ± 0.0495 0.7861
Positive 53 0.3732 ± 0.0320
PR status
Negative 31 0.3426 ± 0.0395 0.4423
Positive 47 0.3850 ± 0.0361
Her2 status
Negative 49 0.3548 ± 0.0326 0.5221
Positive 29 0.3906 ± 0.0469
Li et al. Molecular Cancer 2013, 12:163 Page 4 of 13
http://www.molecular-cancer.com/content/12/1/163Figure 3D, the ectopic expression of miR-124 inhibited
FLOT1 expression by approximately 60% to 70%. There-
fore, we concluded that miR-124 inhibited FLOT1 ex-
pression by binding to the 3′-UTR sequences of FLOT1
in breast cancer.
Knockdown of FLOT1 induced inhibition of breast cancer
cells proliferation and invasion
To explore the function of FLOT1 in breast cancer,
MDA-MB-231 and T47D cells were transfected with
FLOT1-specific siRNAs (FLOT1-siRNA). A western blot
analysis indicated that FLOT1 protein decreased signifi-
cantly after 48 hours in both MDA-MB-231 and T47D
cells transfected with 50 nM FLOT1-siRNA (Figure 4A).
The MTT and colony formation assays showed that the
knockdown of FLOT1 inhibited the proliferation and
growth of both MDA-MB-231 and T47D cells (Figure 4B;
P < 0.05). Furthermore, a Matrigel invasion assay indicated
that the knockdown of FLOT1 inhibited the invasion of
breast cancer cells (Figure 4C), an effect that resembled
the inhibitory effect of miR-124 in breast cancer cells.
To test whether FLOT1 is the direct functional medi-
ator of the miR-124 induced inhibition of breast cancer
cell proliferation and migration, we co-transfected miR-124 mimics along with wt/mut 3′-UTR-FLOT1 plasmid
which FLOT1 cDNA contained wild type or mutant 3′
UTR into breast cancer cells. MTT and Matrigel inva-
sion assays showed that mut 3′-UTR-FLOT1 could par-
tially abrogate the miR-124-mediated effects in breast
cancer cells, to restore the proliferation and migration
compared with the miR-Ctrl (Figure 4D and E; P < 0.05).
Therefore, FLOT1 has an important role in the prolifer-
ation and invasion of breast cancer cells, which was reg-
ulated by miR-124.
MiR-124 and FLOT1 are inversely correlated in breast
cancer tissues
IHC was performed to detect FLOT1 expression in 5
normal breast tissues and 78 clinical breast cancer speci-
mens, and the miR-124 expression levels were simultan-
eously analyzed by RT-PCR. These cases included 21
cases of clinical stage I, 41 cases of stage II, 13 cases of
stage III, and 3 cases of stage IV breast cancers. FLOT1
was found to be predominantly overexpressed in the
cytoplasm and membranes of breast cancer tumor cells
and was less expressed in adjacent normal tissues
(Figure 5A). In consensus with previous report [26], our
data also showed that FLOT1 expression in stage I to IV
primary tumors was statistically higher than in normal
breast tissues (P < 0.05, Figure 5B). We then correlated
FLOT1 with the miR-124 expression levels in the same
breast cancer specimens. As shown in Figure 5C, a sig-
nificant inverse correlation was observed when FLOT1
expression levels were plotted against miR-124 expres-
sion levels (2-tailed Spearman’s correlation, r = −07437;
P <0.0001).
Discussion
Cancer is characterized by abnormal and uncontrolled
cell proliferation, which is caused not only by the misre-
gulation of several pivotal proteins but also by a systemic
change in the miRNAs profile [28]. MiRNAs are in-
volved in the regulation of multiple biological processes,
including development, cell proliferation, apoptosis, dif-
ferentiation, disease survival and cell death [29,30]. Con-
sidering the function of miRNAs, their deregulation
expectedly contributes to substantial cell physiological
and pathological processes and is ultimately involved in
tumorigenesis and the tumor progression of many differ-
ent human cancers. In this report, we showed that miR-
124 was markedly downregulated in human breast cancer
cell lines and clinical specimens compared with immor-
talized normal mammary epithelial cell lines and normal
adjacent tissues, respectively. MiR-124 downregulation
was significantly associated with advanced clinical stage
and positive lymph node-metastasis in breast cancer pa-
tients. Furthermore, the ectopic expression of miR-124
inhibited breast cancer cell proliferation, migration and
Figure 2 (See legend on next page.)
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Figure 2 Ectopic expression of miR-124 suppresses breast cancer cell proliferation, migration and invasion. A, miR-124 was re-expressed
in MDA-MB-231 and T47D cells by transfection of miR-124 mimics. Forty-eight hours later, the miR-124 expression levels were tested by quantitative
RT-PCR and normalized to 5S rRNA. B, Analysis of the effect of miR-124 on the proliferation of MDA-MB-231 and T47D cells by MTT assay. C, Cell cycle
arrest effect of miR-124 on MDA-MB-231 and T47D cells monitored with flow cytometric. D, Colony formation assay demonstrated that the effect of
miR-124 on the cell growth of MDA-MB-231 and T47D cells. E, Analysis the effect of miR-124 on the migration of MDA-MB-231 and T47D cells by
wound-healing assay. F, A Matrigel invasion chamber was utilized to analyze the effect of miR-124 on the cell invasion of MDA-MB-231 and T47D cells.
The data represent the mean values of three independent experiments. *, P < 0.05 with paired t-test.
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and functional target of miR-124 via binding to the 3′
UTR of FLOT1. Our study suggested that miR-124 acts as
a novel proliferation and metastasis suppressor in breast
cancer, and downregulated miR-124 contributes to lymph
node-metastasis and tumor progression in breast cancer
patients.
Although miR-124 was identified long ago, its biological
function has only recently been investigated. MiR-124 acts
as a tumor suppressor, and its downregulation has been
identified in various cancers [16,18-22,31-33], which sug-
gests that miR-124 may play a vital role in tumorigenesis
and tumor progression. Shi et al. showed that miR-124 was a
potential tumor-suppressive miRNA and was downregulatedFigure 3 MiR-124 directly regulates FLOT1 by binding to the FLOT1 3
and interspecies conservation of seed matching sequences (gray box). B, D
reporter assays in MDA-MB-231 cells. Co-transfected of wt/mut 3′-UTR with
miR-124 transfected at 50 nM in MDA-MB-231 and T47D by western blot asin prostate cancer to result in proliferation inhibition of
prostate cancer cells by targeting the androgen receptor
[20]. Wang et al. reported that miR-124 was epigenetically
silenced in pancreatic cancer and inhibited cell prolifera-
tion and metastasis by regulating Rac1 [17]. Zheng et al.
showed that miR-124 levels were frequently reduced in
hepatocellular carcinoma, and this expression level was
significantly associated with the patients’ clinical stages
and prognoses and regulated the invasion and migration
of hepatocellular carcinoma through post-transcriptional
regulation of ROCK2 and EZH2 [19]. Lv et al., Liang et al.
and Han et al. also reported that miR-124 can suppress
breast cancer growth and metastasis [16,21,22]. Han et al.
found that miR-124 is downregulated in breast cancer and′-UTR. A, Putative miR-124 binding site in the 3′-UTR region of FLOT1
iagram of FLOT1 3′-UTR contained reporter constructs. C, Luciferase
miRNAs as indicated. D, Expression levels of FLOT1 are tested after
say. *, P < 0.05 compared with control.
Figure 4 (See legend on next page.)
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Figure 4 FLOT1 is essential for breast cancer cell proliferation and invasion, and involved in the miR-124-induced inhibition of cell
proliferation and migration. A, Analysis of protein expression by western blot, FLOT1 protein is reduced by small interfering RNA (FLOT1-siRNA)
in MDA-MB-231 and T47D cells. B, MTT assay show that cell proliferation is inhibited in MDA-MB-231 and T47D cells after transfection of FLOT1-siRNA
compared with scrambled sequence (Ctrl-siRNA). C, Cell invasion of MDA-MB-231 and T47D cells after knockdown of FLOT1 are evaluated by Matrigel
invasion chamber. D, MTT assay shows cell proliferation in MDA-MB-231 and T47D cells co-transfected with miR-124 and wt/mut 3′-UTR-FLOT1
compared with scrambled miRNA mimics (miR-Ctrl). E, Cell invasion ability of MDA-MB-231 and T47D cells which co-transfection of miR-124 and
wt/mut 3′-UTR-FLOT1 were evaluated by Matrigel invasion chamber compared with scrambled miRNA mimics (miR-Ctrl). *, P < 0.05 compared
with control.
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vasion and metastatic ability, likely by directly targeting
the CD151. CD151 regulates the ligand biding activity of
integrin α3β1 and plays a role in Met-dependent signaling
and TGF-β signaling, while c-met can regulate many cel-
lular process, especially the proliferation and migration of
cancer. These results suggest an important role for miR-
124 in the proliferation and metastasis of different can-
cers. However, the miR-124 expression levels in clinical
specimens and its exact mechanism in breast cancer has
not been clearly elucidated. In this study, we demonstrated
for the first time that miR-124 was frequently downregu-
lated in breast cancer, and the average expression levels of
miR-124 were significantly downregulated in breast cancer
tissues compared with paired normal adjacent tissues.
Interestingly, we found that lower levels of miR-124 are
associated with advanced TNM stage (stage I + II vs. stage
III + IV, P = 0.0007) and positive lymph node metastasis,
suggesting that a low expression of miR-124 is associatedFigure 5 MiR-124 and FLOT1 are inversely correlated in breast cancer
tissues, and breast cancer specimen with different clinical stages. B, Statisti
tissues and breast cancer specimen with different clinical stages. C, A scatte
expression in the same set of breast cancer tissue (Spearman’s correlation awith breast cancer progression. Recently, miR-124 was re-
ported to be subject to epigenetic regulation in various tu-
mors, including breast cancer [17,31,32,34], which in turn
may explain the downregulation of miR-124 in breast can-
cer. Taken together, these results suggest that miR-124 ex-
pression is frequently reduced in breast cancer, which may
be responsible for the tumorigenesis and progression of
breast cancer. However, the function of miR-124 in breast
cancer is not fully understood.
The capability of cells to proliferate, migrate and in-
vade is considered an important determinant in the
process of tumorigenesis and progression. Many onco-
genes and suppressor genes reportedly correlate with the
course of cancer initiation and progression, but the mo-
lecular mechanisms are not fully understood. Recently,
accumulating studies have reported that miRNAs play
important roles in breast cancer tumorigenesis and pro-
gression [35-37]. Interestingly, a number of miRNAs are
associated with the proliferation and migration of breasttissues. A, Representative IHC analysis of FLOT1 in normal breast
cal quantification of the IHC scores of FLOT1 between normal breast
r diagram shows an inverse correlation between miR-124 and FLOT1
nalysis, r = −7437; P < 0.0001).
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[40], and miR-210 [41], which may provide new insights
into the design of eradicating therapeutic strategies for
breast cancer. Even miR-124 has been reported as a
tumor suppressor miRNA in breast cancer. However, the
mechanisms involved have not been fully elucidated. To
determine the function of miR-124 in breast cancer, we
tested the effect of miR-124 on MDA-MB-231 and
T47D cell lines. Ours results indicate that miR-124 could
suppress breast cancer cell proliferation, migration and
invasion, which suggests its role as a tumor suppressor
in breast cancer.
In the current study, we identified FLOT1 as a direct
and functional target of miR-124. The protein encoded
by the FLOT1 gene is an integral membrane protein that
participates in vesicular trafficking, signal transduction
and is important for lipid raft formation [25,26,42]. Ac-
cumulating evidence shows that the overexpression of
FLOT1 in various cancers contributes to proliferative
and invasive behavior as well as a worse prognosis
[24-26]. The knockdown of FLOT1 reportedly sup-
pressed the proliferation and tumorigenesis of breast
cancer cells by enhancing the transcriptional activity of
FOXO3a, inhibiting Akt activity, downregulating cyclin
D1 and upregulating the cyclin-dependent kinase inhibi-
tors p21Cip1 and p27Kip1 [26]. Xiong et al. also showed
that Flotillin-1 could clearly activate the growth and me-
tastasis of oral squamous carcinoma by transfecting cells
with a Flotillin-1 expression vector or shRNA targeted
Flotillin-1. This effect was mediated by the activation of
the NF-κB signaling pathway, which enhanced the phos-
phorylation of p65 and IκBα [23]. These studies showed
that FLOT1 can regulate many cellular processes, par-
ticularly in cancer growth, proliferation, migration, me-
tastasis and tumorigenesis. Consistent with the study
above, we found that miR-124 could directly target and
downregulate FLOT1, and high FLOT1 expression was
associated with low miR-124 levels in breast cancer
specimens. These findings provide new insight into the
essential mechanisms of FLOT1 regulation in breast
cancer. Additionally, miR-138 was also reported to regu-
late FLOT1 in esophageal squamous cell carcinoma.
These findings suggest that the post-transcriptional
regulation of FLOT1 by miRNAs is a vital mechanism
underlying cancer proliferation and metastasis, and miR-
124 may serve as potential treatment target for regulating
FLOT1 to inhibit the growth and metastasis of breast
cancer.
Conclusions
Our study demonstrates that miR-124 is downregulated
and inversely associated with the lymph node metastasis
in breast cancer. The ectopic expression of miR-124 in-
hibits cell proliferation and migration by downregulatingFLOT1, which indicates the internal mechanism of
tumor suppression of miR-124. Combined with the
above mentioned studies, this work contributes to the
understanding of the effect of miR-124 on tumor sup-
pression. This study suggests that miR-124 downregu-
lated may play an important role in tumor proliferation
and migration and may be a novel diagnostic marker
and potential therapeutic target in breast cancer.
Materials and methods
Human breast cancer tissues
78 cases of human breast cancer and 40 corresponding
normal breast tissues were collected at the time of surgi-
cal resection from the First Affiliated Hospital of Sun
Yat-sen University and Sun Yat-sen University Cancer
Center from (Guangzhou, China) 2009 to 2011. The
samples were fixed in RNAlater (Ambion, Austin, TX,
USA) immediately after surgical resection and stored at
−80°C in a freezer until use. The breast cancer samples
selected were based on a clear pathological diagnosis,
and the clinical information for the samples is presented
in Table 1. The tumor stage was defined according to
the American Joint Committee on Cancer and tumor-
lymph node-metastasis classification system [43]. All pa-
tients provided consent for the use of their specimens in
research, and this use was approved by the institute
research ethics committee of the First Hospital of Sun
Yat-sen University.
Immunohistochemical staining
Inmmunohistochemistry (IHC) staining of formalin-
fixed and paraffin-embedded tissue slides was performed
and quantified as previously described [44]. Briefly, 5 μm
tissue slides were deparaffinized, rehydrated via a series
of descending graded alcohols and subjected to antigen
retrieval in 0.01 M citrate buffer (pH 6.0) at 90°C for
40 minutes. Following a blocking step, the slides were
incubated with FLOT1 primary antibody (1:500; Sigma,
Saint Louis, MO) and washed. Biotinylated secondary
antibody was applied, and the immunocomplexes were
visualized using an avidin-biotin complex immunope-
roxidase system (Vector Laboratories, Burlingame, CA,
USA) with 0.03% diaminobenzidine (DAB) as a chromagen
and hematoxylin as the counterstain. We used phosphate-
buffered saline (PBS) instead of the primary antibody as
a negative control, and a composite slide containing
formalin-fixed cell pellets of MDA-MB-231 and T47D
as positive control to assess the quality of the IHC reac-
tion. The slides were reviewed and scored independently
based on both the percentage of positive stained tumor
cells and overall stained intensity by two observers who
were blinded to specimens’ clinical information. The fol-
lowing scoring rubric was used: scored 0, absent positive
tumor cells; scored +, weak cell staining or <10%
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or 10-50% positive tumor cells; scored +++, strong cell
staining or >50% positive tumor cells. Conflicts (ap-
proximately 5% of cases) were resolved by consensus.
Cell culture
The breast cancer cell lines MDA-MB-231, MDA-MB-
361, MDA-MB-435, MDA-MB-468, MCF-7, HBL100,
T47D, and 4 T1 and two immortalized normal mammary
epithelial cell lines, MCF-10A and 184A1, were obtained
from the American Type Culture Collection (Manassas,
VA) and freshly recovered from liquid nitrogen (<3 months).
The breast cancer cells were maintained according to
the vendor’s instructions. Briefly, the breast cancer cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) or RPMI 1640 (Invitrogen, Beijing, China)
supplemented with 10% fetal bovine serum (FBS,
GIBCO, Cappinas, Brazil). MCF-10A cells were cultured
in Keratinocyte-SFM (Invitrogen, CA, USA) supple-
mented with pre-qualified human recombinant epider-
mal growth factor 1–53 (EGF 1–53, Invitrogen, CA,
USA) and bovine pituitary extract (BPE, Invitrogen, CA,
USA). The 184A1 cells were cultured in Mammary Epi-
thelium Basal Medium (MEBM, Clonetics, MD, USA).
All cells were grown and maintained at 37°C in a 5%
CO2 humidified incubator (Thermo Electron Corp, New
Castle, DE).
Bioinformatics
The analysis of miR-124 predicted targets was deter-
mined using the algorithms of TargetScan 5.1 (http://
www.targetscan.org/) and miRanda (http://www.micro-
rna.org). According to these algorithms, we predicted
that the FLOT1 gene might be a direct target of miR-124.
Transient transfection of miRNA and siRNA
The miR-124 mimics, a non-specific miRNA negative
control (miR-Ctrl), small interfering RNA (siRNA) du-
plexes targeting human FLOT1 (FLOT1-siRNA) (sense
strand, 5′-ACAGAGAGAUUACGAACUGAAdTdT-3′ and
antisense strand, 5′-UUCAGUUCGUAAUCUCUCUGUd
TdT-3′) and scrambled control siRNA (Ctrl-siRNA)
(sense strand, 5′-UUCUCCGAACGUGUCACGUdTdT-
3′ and antisense strand, 5′-ACGUGACACGUUCGGA-
GAAdTdT-3′) were synthesized and purified by RiboBio
(Guangzhou, China). MiRNA mimics or siRNA duplexes
were transfected at working concentrations of 50 nM
using Lipofectamine 2000 reagent (Invitrogen, CA, USA),
according to the manufacturer’s instruction.
RNA extraction and quantitative real-time PCR
The RNA extraction and quantitative real-time PCR
procedure were carried out as previously reported [39].
Briefly, total RNA was extracted using TRIzol® Reagent(Invitrogen, CA, USA). To quantitate the miR-124 ex-
pression, reverse transcription was performed with a
specific stem-loop real-time PCR miRNA kit (RiboBio,
Guangzhou, China). Quantitative real-time PCR (qPCR)
was performed using the Platinum SYBR Green qPCR
SuperMix-UDG system (Invitrogen, CA, USA) on an
Applied Biosystems 7900HT real-time PCR system, and
the data were collected and analyzed using ABI SDS ver-
sion 2.3. All procedures were performed according to the
manufacturer’s instructions. 5S rRNA was used as an in-
ternal control. All samples were normalized to internal
controls, and the fold changes were calculated according
to the relative quantification method (RQ = 2−ΔΔCT). The
results are shown as fold changes of expression in cells or
cancer tissues.
The primers of miR-124 and 5S rRNA used for stem-loop




verse, 5′-GTGCAGGGTCCGAGGT-3′; 5S rRNA stem-
loop RT, 5′-GTCGTATCCAGTGCAGGGTCCGAGGTA




The cell viability and proliferation of MDA-MB-231 and
T47D with miRNA mimics or siRNA duplexes were de-
termined by 3-(4, 5-dimethylthiazolyl-2-yl)-2-5 diphenyl
tetrazolium bromide (MTT, Sigma, St. Louis, MO, USA)
assay. The cells were plated in 96-well plates at 5 × 103
per well in a final volume of 100 μL and treated with
miRNA mimics or siRNA duplexes. After incubation for
24, 48, 72 and 96 hours, the culture medium was replaced
with 100 μL of fresh DMEM. Twenty-five microliters of
MTT stock solution (5 g L-1 in phosphate-buffered saline)
were added to each well to achieve a final concentration
of 1 g L-1. The plates were incubated for another 4 hours,
the culture medium was replaced with dimethyl sulfoxide
(DMSO, Sigma, St. Louis, MO, USA), and the absorbance
was measured at 570 nm by a SpectraMax M5 Microplate
Reader (Molecular Deviced, Sunnyvale, CA, USA). The
cell viability was normalized to that of cells cultured in the
culture medium without miRNA mimics or siRNA du-
plexes. Three independent experiments (3 replicates in
each) were performed.
Wound healing assay
To determine cell migration, MDA-MB-231 and T47D
breast cancer cells transfected with miRNA mimics were
seeded in six-well plates, incubated in their respective
complete culture medium and grown to confluence over-
night. Wounds were made by scraping with a sterilized
Li et al. Molecular Cancer 2013, 12:163 Page 11 of 13
http://www.molecular-cancer.com/content/12/1/163200 μL pipette tip, and the debris was rinsed with
phosphate-buffered saline. Serial photographs were ob-
tained at 0, 24 and 48 hours using a phase contrast
microscope (Olympus IX81, Tokyo, Japan).
MiRNA-transfected cells were scratched using a stand-
ard 200 μL tip. The debris was removed by washing with
serum-free medium. Serial photographs were obtained at
different time points using a phase contrast microscope
(Olympus IX81, Tokyo, Japan). Three independent ex-
periments were carried out.
Transwell invasion assays
To determine cell invasion in vitro, Matrigel-coated in-
vasion chambers (8 μm; BD Biosciences, CA, USA) were
used according to the manufacturer’s protocol. Briefly,
miRNA mimic- or siRNA duplex-transfected cells were
harvested, re-suspended (1 × 105 cells per well) in 200 μL
serum-free medium, and transferred to the upper cham-
ber of the Matrigel-coated inserts; culture medium con-
taining 10% FBS was placed in the bottom chamber. The
cells were incubated for 24 hours at 37°C; the cells on the
upper surface were then removed by peeling off the matri-
gel and swiping the top of the membrane with cotton
swabs. The cells that had invaded the lower surface were
fixed and stained with 0.5% crystal violet (Sigma, St Louis,
MO, USA) for 30 min, counted under an inverted micro-
scope (Olympus IX71, Tokyo, Japan), and the relative num-
ber of invading cells was calculated from five-field digital
images taken randomly at 200× magnification. The data
are the means ± SD of three independent experiments.
Cell cycle assays
To determine cell cycle distribution, the cells were plated
in 6-well plates and transfected with miRNA mimics or
siRNA duplexes. After transfection, the cells were col-
lected by trypsinization, fixed in 70% ethanol, washed in
PBS, re-suspended in 200 ml of PBS containing 1 mg/ml
RNase, 0.05% Triton X-100 and 50 mg/ml propidium iod-
ide (Sigma, St Louis, MO, USA), incubated for 30 min at
37°C in the dark, and analyzed immediately using a FACS-
Calibur instrument (Becton Dickinson, CA, USA). The
data were analyzed using the CellQuest Pro software (BD
Biosciences).
Colony formation assays
After transfecting with miRNA mimics or siRNA du-
plexes, the cells were seeded in 6-well plates at 5 × 102
per well and incubated for 2 weeks for the colony forma-
tion assay.
The cells were then washed twice with PBS, fixed with
methanol/acetic acid (3:1, v/v), and stained with 0.5%
crystal violet (Sigma, St Louis, MO, USA). The number
of colonies was counted under the microscope (Olympus
IX81, Tokyo, Japan).Plasmid
The 3′-untranslated regions (3′-UTR) sequences of hu-
man FLOT1 containing the putative miR-124 binding
sites were isolated from MDA-MB-231 cDNA using
PCR amplification and cloned into the pGL3 vector
(Promega, Madison, WI, USA), which was termed as
wild-type 3′-UTR (wt 3′-UTR). The point mutations in
the putative miR-124 binding seed regions were per-
formed using the Quick-Change Site-Directed Mutagen-
esis kit (Stratagene, La Jolla, CA, USA) according to the
manufacturer’s protocol. The resultant product served as
the mutated 3′-UTR (mut 3′-UTR). Both the wild-type
and mutant insert fragments sequences were confirmed
by DNA sequencing.
For FLOT1 overexpression, the cDNA of FLOT1 con-
taining the putative miR-124 binding sites was cloned
into the multiple cloning site of the pcDNA3.1 vector
(Invitrogen, Carlsbad, CA, USA), which was termed as
wild-type 3′-UTR-FLOT1 (wt 3′-UTR-FLOT1). The
mut 3′-UTR-FLOT1 was obtained as described above.
In the rescue experiment, cells were cotransfected with
50 nM of miRNA mimics and 500 ng of plasmid in a
six-well plate.
Luciferase assays
The cells were seeded in triplicate in 24-well plates one
day before transfection for the luciferase assays. Wt or
mut 3′-UTR vectors and the control vector pRL-TK
(Promega, Madison, WI, USA) coding for Renilla luci-
fearse were co-transfected with miR-124 mimics or
negative control into MDA-MB-231 cells using Lipofec-
tamine 2000 reagent, as described previously. After
48 hours of transfection, the cells were harvested and
lysed, and the luciferase activity was assayed using the
Dual-Glo luciferase assays kit (Promega, Madison, WI,
USA). The firefly luciferase values were normalized to
Renilla, and the relative ratios of firefly to Renilla activity
were reported. Three independent experiments were
performed, and the data are presented as the mean ± SD.
Western blot analysis
Transfected MDA-MB-231 and T47D cells were cul-
tured for 72 hours and then harvested on ice using RIPA
lysis and extraction buffer (25 mM Tris–HCl pH 7.6,
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate,
0.1% SDS, protease inhibitor cocktail (Pierce, Rockford,
IL). The total cell extracts (20 μg protein) were separated
using 10% SDS-polyacrylamide gels and electrophoretic-
ally transferred to polyvinylidene difluoride membranes
(PVDF, Millipore, MA, USA). The membranes were in-
cubated with mouse monoclonal antibody against hu-
man FLOT1 (Sigma, St Louis, MO, USA) followed by
horseradish peroxidase (HRP)-conjugated goat-anti-
mouse IgG (Abcam), and the bands were detected using
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(Pierce) and Kodak X-ray film (Eastman Kodak Co, NY,
USA); an anti-tubulin antibody (Sigma, St Louis, MO,
USA) was used as a protein loading control.
Statistical analysis
All experiments were performed at least three times,
and all samples were tested in triplicate. The data are
shown as the mean ± SEM unless otherwise noted; Stu-
dent’s t-test was used for statistical analysis when only
two groups were tested. A one-way analysis of variance
was used to compare multiple groups. The difference in
miR-124 and FLOT1 expressions between breast cancer
specimens and normal adjacent tissues of human sub-
jects was calculated by a two-tailed independent samples
t-test. Spearman’s correlation analysis was used to deter-
mine the correlation between miR-124 and FLOT1 expres-
sions. In all cases, a P < 0.05 was considered statistically
significant.
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